Skip to main content
Veterinary Medicines

Marfloquin 5 mg Tablets for Cats and Dogs

Authorised
  • Marbofloxacin

Product identification

Medicine name:
Marfloquin 5 mg Tablets for Cats and Dogs
Marfloquin 5 mg Tabletten für Katzen und Hunde
Active substance:
  • Marbofloxacin
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Marbofloxacin
    5.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01MA93
Authorisation status:
  • Valid
Authorised in:
  • Austria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka d.d. Novo Mesto
  • Krka-Farma d.o.o.
Responsible authority:
  • Austrian Agency For Health And Food Safety
Authorisation number:
  • 8-01142
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0322/001
Concerned member states:
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Netherlands
  • Portugal
  • United Kingdom (Northern Ireland)

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 20/12/2021

Summary of Product Characteristics

English (PDF)
Published on: 22/12/2023
Download
German (PDF)
Published on: 15/05/2018

Labelling

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 15/05/2018
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."